作者
William R. Freeman,Francesco Bandello,Eric Souied,Robyn H. Guymer,Sunir J. Garg,Fred K. Chen,Ryan Rich,Frank G. Holz,Sunil S. Patel,Kimmie Kim,Francisco J. López,Fred Chen,Robyn Guymer,Jean-Francois Korobelnik,Eric Souied,Frank Holz,Focke Ziemssen,Francesco Bandello,Emilio Campos,Chiara Grignolo/Eandi,Edoardo Midena,Enrico Peiretti,Giovanni Staurenghi,Francesco Viola,Clare Bailey,Simona Degli Esposti,Timothy Jackson,Geeta Menon,Sergio Pagliarini,Fahd Quhill,Andrew Antoszyk,Logan Brooks,David Callanan,Karl Csaky,Albert Edwards,David Eichenbaum,William Freeman,Sunir Garg,Avtar Thomas Ghuman,Victor Gonzalez,Sunil Gupta,Richard Hamilton,Rahul Khurana,Derek Kunimoto,Baruch Kuppermann,Andreas Lauer,Seong Young Lee,Raj Maturi,Sunil Patel,Rahul Reddy,Ryan Rich,Mark Rivellese,Steven Rose,Zachary Segal,Robert Wong
摘要
To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400 μg brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).Phase 2b, randomized, multicenter, double-masked, sham-controlled, 30-month study (BEACON).Patients diagnosed with GA secondary to AMD and multifocal lesions with total area >1.25 mm2 and ≤18 mm2 in the study eye.Enrolled patients were randomized to treatment with intravitreal injections of 400-μg Brimo DDS (n=154) or sham procedure (n=156) in the study eye every 3 months from day 1 through month 21.The primary efficacy endpoint was change from baseline in the GA lesion area in the study eye, assessed with fundus autofluorescence imaging, at month 24. Safety measures included treatment-emergent adverse events (AEs).The study was terminated early, at the time of the planned interim analysis, because of a slow GA progression rate (∼1.6 mm2/year) in the enrolled population. Least-squares mean (standard error) GA area change from baseline at month 24 (primary endpoint) was 3.24 (0.13) mm2 with Brimo DDS (n=84) versus 3.48 (0.13) mm2 with sham (n=91); the reduction in GA area change from baseline in the Brimo DDS group compared with the sham group was 0.25 mm2 (7%) (P = 0.150). At month 30, the GA area change from baseline was 4.09 (0.15) mm2 with Brimo DDS (n=49) versus 4.52 (0.15) mm2 with sham (n=46), a reduction of 0.43 mm2 (10%) with Brimo DDS compared with sham (P=0.033). Exploratory analysis showed numerically smaller loss over time in retinal sensitivity assessed with scotopic microperimetry with Brimo DDS compared with sham (P=0.053 at month 24). Treatment-related AEs were usually related to the injection procedure. No implant accumulation was observed.Multiple intravitreal administrations of Brimo DDS (Gen 2) were well tolerated. The primary efficacy endpoint at 24 months was not met, but there was a numerical trend for reduction in GA progression at 24 months compared with sham treatment. The study was terminated early because of the lower-than-expected GA progression rate in the sham/control group.